What is Emergent BioSolutions Inc.'s (EBS) StockRank?

MoatMap's StockRank for Emergent BioSolutions Inc. (EBS) is 80/100, with a Strong Buy signal. This is a composite score combining Quality (63), Value (73), and Momentum (38) factor ranks across MoatMap's 20,000+ stock universe.

Does Emergent BioSolutions Inc. have an economic moat?

Emergent BioSolutions Inc. (EBS) has a Quality factor score of 63/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the financial characteristics of a moated business.

Is Emergent BioSolutions Inc. a buy, hold, or sell?

MoatMap's current signal for Emergent BioSolutions Inc. (EBS) is Strong Buy, based on a StockRank of 80/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.

What sector is Emergent BioSolutions Inc. in?

Emergent BioSolutions Inc. (EBS) operates in the Healthcare sector, specifically the Drug Manufacturers - Specialty & Generic industry (United States).

Company Deep Dive

Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.

Request Deep Dive(50 Feathers)

EBS

STRONG BUYFLAG

Emergent BioSolutions Inc. · Healthcare · United States · $375M · Avg Vol: $6M/d

StockRank

Get insider-trade alerts

P/E (TTM)

—

ROE

-1.6%

D/E

1.1x

Dividend %

—

AI CONVICTION THESIS

Emergent BioSolutions has value V73 with a buyback on file, but momentum at M43 is below the calibrated floor, and insiders sold 0.13%, which is separately adverse.

COMPANY DESCRIPTION

Emergent BioSolutions Inc. is a biopharmaceutical company focused on providing specialized products that address public health threats, including medical countermeasures and vaccines. The company develops, manufactures, and commercializes products for anthrax, smallpox, and opioid overdose, serving government agencies and commercial markets. Its unique focus on biodefense and public health readiness establishes a niche market leadership with long-term government contracts.

FINANCIAL SUMMARY (USD)

Year	2022	2023	2024	2025	CAGR	TTM
Revenue	1.1B	1.0B	1.0B	705.2M	-13.1%	676.8M
EPS	-4.47	-14.85	-3.60	0.98	—	-0.19
Shares	50.1M	52.2M	54.3M	52.1M	+4.0%	51.6M
Debt	1.4B	860.2M	663.7M	572.1M	-25.9%	584.6M
Equity	1.4B	649.3M	482.8M	522.6M	-27.8%	—
Op CF	-34.1M	-206.3M	58.7M	170.6M	190.6%	148.0M
Inv CF	-381.3M	212.3M	125.2M	69.4M	—	—
Fin CF	481.2M	-535.7M	-190.0M	-136.6M	—	—

Loading 1Y...

PRICE (1Y)-11.9%

SMA 50SMA 200

$7.33

RSI (14)

26.9

52W High

$14.06

From 52W High

0.5%

SCORE BREAKDOWN

Quality

ROIC

12.0%79.7

ROE

-1.6%44.2

GP/Assets

24.4%56.5

Op. Margin

6.8%60.2

FCF/Assets

19.4%96.0

Piotroski

893.2

Int. Cover

2.4x44.7

D/E Ratio

1.12x12.6

Current Ratio

4.29x66.3

Value

P/E (TTM)

—N/A

EV/EBITDA

4.9x92.5

P/FCF

1.5x98.7

P/B

0.8x90.7

P/S

0.6x90.9

Div Yield

—N/A

Momentum

52W High %

52%28.0

RS 6M

-46%16.7

SMA 50/200

0.84x27.5

EPS Rev 4W

0.0%62.6

EPS Rev 12W

0.0%56.8

EPS Improve

+1674%99.1

Q Growth

-90%1.6

FUNDAMENTALS

Market Cap

$375M

P/E (Forward)

2.6x

Gross Margin

47.5%

SECTOR PEERS

Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of EBS are excluded.

Ticker	Company	Mkt Cap	StockRank	Signal
EBS	Emergent BioSolutions Inc.(you)	$375M	80	STRONG BUY
SIGA	SIGA Technologies, Inc.	$223M	76	BUY
ANIK	Anika Therapeutics, Inc.	$199M	76	BUY
AMPH	Amphastar Pharmaceuticals, Inc.	$825M	75	BUY
IRWD	Ironwood Pharmaceuticals, Inc.	$611M	97	STRONG BUY
CL.CN	Cresco Labs Inc.	$263M	57	HOLD
PAHC	Phibro Animal Health Corporation	$1.4B	76	BUY
PCRX	Pacira BioSciences, Inc.	$1.0B	93	STRONG BUY
TRLV	Trulieve Cannabis Corp.	$1.6B	87	STRONG BUY
COLL	Collegium Pharmaceutical, Inc.	$1.1B	95	STRONG BUY

Peer medians: ROE -25.6% · P/E 27.7x · Gross margin 50.7%

Emergent BioSolutions Inc. (EBS) — Stock Score Summary

Emergent BioSolutions Inc. (EBS) has a MoatMap StockRank of 80/100 based on Quality (63/100), Value (73/100), and Momentum (38/100) factor scores. The current signal is STRONG BUY. Emergent BioSolutions has value V73 with a buyback on file, but momentum at M43 is below the calibrated floor, and insiders sold 0.13%, which is separately adverse.

Key Financial Metrics

Price	$7.33
Market Cap	$375M
P/E (Forward)	2.57
Price/Book	0.76
Return on Equity	-1.6%
Return on Invested Capital	12.0%
Debt/Equity	1.12x
Gross Margin	47.5%
Operating Margin	6.8%
Revenue Growth	-29.7%
Free Cash Flow	$256M

Emergent BioSolutions Inc. operates in the Drug Manufacturers - Specialty & Generic industry, part of the Healthcare sector (United States).

Frequently Asked Questions

What is Emergent BioSolutions Inc.’s (EBS) StockRank?: MoatMap’s StockRank for Emergent BioSolutions Inc. (EBS) is 80/100, with a Strong Buy signal. It is a composite of Quality (63), Value (73), and Momentum (38) factor ranks across MoatMap’s 20,000+ stock universe.
Does Emergent BioSolutions Inc. have an economic moat?: Emergent BioSolutions Inc. (EBS) has a Quality factor score of 63/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the characteristics of a moated business.
Is Emergent BioSolutions Inc. a buy, hold, or sell?: MoatMap’s current signal for Emergent BioSolutions Inc. (EBS) is Strong Buy, based on a StockRank of 80/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.
What sector is Emergent BioSolutions Inc. in?: Emergent BioSolutions Inc. (EBS) operates in the Healthcare sector, specifically the Drug Manufacturers - Specialty & Generic industry (United States).